Overview

Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes

Status:
Withdrawn
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled parallel group study of HU6 and placebo in subjects who are overweight or obese with T2D. The study will be conducted in 4 stages.
Phase:
Phase 2
Details
Lead Sponsor:
Rivus Pharmaceuticals, Inc.